Zimmer Biomet Ownership

ZBH Stock  USD 110.73  1.05  0.94%   
Zimmer Biomet Holdings retains a total of 199.06 Million outstanding shares. The majority of Zimmer Biomet outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zimmer Biomet Holdings to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zimmer Biomet Holdings. Please pay attention to any change in the institutional holdings of Zimmer Biomet Holdings as this could imply that something significant has changed or is about to change at the company. Please note that on March 13, 2025, Representative Julie Johnson of US Congress acquired under $15k worth of Zimmer Biomet Holdings's common stock.
 
Shares in Circulation  
First Issued
2009-03-31
Previous Quarter
203 M
Current Value
204 M
Avarage Shares Outstanding
198.4 M
Quarterly Volatility
14.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Zimmer Biomet in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Zimmer Biomet, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Zimmer Stock Ownership Analysis

About 94.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.77. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zimmer Biomet Holdings has Price/Earnings To Growth (PEG) ratio of 1.51. The entity last dividend was issued on the 31st of March 2025. The firm had 103:100 split on the 1st of March 2022. Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Zimmer Biomet operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 19500 people. For more information please call Bryan Hanson at 574 373 3333 or visit https://www.zimmerbiomet.com.
Besides selling stocks to institutional investors, Zimmer Biomet also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Zimmer Biomet's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Zimmer Biomet's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Zimmer Biomet Quarterly Liabilities And Stockholders Equity

21.37 Billion

Zimmer Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Zimmer Biomet is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zimmer Biomet Holdings backward and forwards among themselves. Zimmer Biomet's institutional investor refers to the entity that pools money to purchase Zimmer Biomet's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Allspring Global Investments Holdings, Llc2024-12-31
2.6 M
Citadel Advisors Llc2024-12-31
2.4 M
Northern Trust Corp2024-12-31
2.4 M
Morgan Stanley - Brokerage Accounts2024-12-31
2.2 M
Norges Bank2024-12-31
M
Dimensional Fund Advisors, Inc.2024-12-31
M
Ubs Asset Mgmt Americas Inc2024-12-31
1.8 M
Hotchkis & Wiley Capital Management Llc2024-12-31
1.7 M
Boston Partners Global Investors, Inc2024-12-31
1.6 M
Vanguard Group Inc2024-12-31
22.9 M
Dodge & Cox2024-12-31
19.1 M
Note, although Zimmer Biomet's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Zimmer Biomet Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zimmer Biomet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Michael Farrell over two months ago
Acquisition by Michael Farrell of 301 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3
 
Shapiro Louis over two months ago
Acquisition by Shapiro Louis of 130 shares of Zimmer Biomet at 105.73 subject to Rule 16b-3
 
Suketu Upadhyay over three months ago
Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3
 
Suketu Upadhyay over three months ago
Disposition of 15948 shares by Suketu Upadhyay of Zimmer Biomet subject to Rule 16b-3
 
Kurdikar Devdatt over three months ago
Acquisition by Kurdikar Devdatt of 127 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3
 
Robert Hagemann over six months ago
Acquisition by Robert Hagemann of 616 shares of Zimmer Biomet at 121.61 subject to Rule 16b-3
 
Van Zuilen Wilfred over six months ago
Disposition of 2633 shares by Van Zuilen Wilfred of Zimmer Biomet subject to Rule 16b-3
 
Sreelakshmi Kolli over six months ago
Acquisition by Sreelakshmi Kolli of 144 shares of Zimmer Biomet at 108.48 subject to Rule 16b-3
 
Paul Stellato over six months ago
Disposition of 627 shares by Paul Stellato of Zimmer Biomet subject to Rule 16b-3
 
Arthur Higgins over six months ago
Acquisition by Arthur Higgins of 1068 shares of Zimmer Biomet subject to Rule 16b-3
 
Van Zuilen Wilfred over six months ago
Acquisition by Van Zuilen Wilfred of 2163 shares of Zimmer Biomet subject to Rule 16b-3
 
Lori Winkler over a year ago
Disposition of tradable shares by Lori Winkler of Zimmer Biomet at 124.28 subject to Rule 16b-3

Zimmer Biomet's latest congressional trading

Congressional trading in companies like Zimmer Biomet Holdings, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Zimmer Biomet by those in governmental positions are based on the same information available to the general public.
2025-03-13Representative Julie JohnsonAcquired Under $15KVerify
2024-12-06Representative Ro KhannaAcquired Under $15KVerify
2017-01-04Senator John ReedAcquired Under $15KVerify

Zimmer Biomet Outstanding Bonds

Zimmer Biomet issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zimmer Biomet Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zimmer bonds can be classified according to their maturity, which is the date when Zimmer Biomet Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Zimmer Biomet Corporate Filings

F3
13th of March 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
F4
7th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
25th of February 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
19th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Currently Active Assets on Macroaxis

When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.41)
Dividend Share
0.96
Earnings Share
4.43
Revenue Per Share
37.807
Quarterly Revenue Growth
0.043
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.